Blue Arrow Capital Management’s Immunogen Inc IMGN Stock Holding History

Blue Arrow Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-34,095	Closed	-$208K	–	213
2014 Q4	$208K	Buy	+34,095	New	+$312K	0.02%	172
2014 Q2	–	Sell	-45,000	Closed	-$672K	–	177
2014 Q1	$672K	Buy	+45,000	New	+$709K	0.1%	91

Other funds holding IMGN

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Blue Arrow Capital Management's IMGN Position: Q1 2015 in Review

Blue Arrow Capital Management sold out of Immunogen Inc (IMGN) in Q1 2015, closing a stake of 34,095 shares — an estimated $208K sold.

Blue Arrow Capital Management first reported a position in IMGN in Q1 2014 and held it in 2 quarters. The position peaked at $672K in Q1 2014. 141 funds tracked by Wall St. Rank hold IMGN as of Q1 2015.

Blue Arrow Capital Management reported no remaining Immunogen Inc position as of Q1 2015 after selling out during the quarter.
Blue Arrow Capital Management sold 34,095 Immunogen Inc shares in Q1 2015, an estimated $208K.
Blue Arrow Capital Management first reported a position in Immunogen Inc in Q1 2014 and held it in 2 quarters.
Blue Arrow Capital Management's Immunogen Inc position peaked at $672K in Q1 2014.
141 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2015.

Based on Blue Arrow Capital Management's 13F filing for Q1 2015, filed 15 May 2015.